JJH201701

JJH201701 is a preclinical-stage small molecule deuterated compound being developed by Jiangsu Jibeier Pharmaceutical for the treatment of gastric acid-related conditions. Developed as part of the company's specialized deuterated drug R&D platform, it is described as a first-in-line innovative antacid candidate. The compound is currently undergoing preclinical evaluation in compliance with national regulatory standards for new drug development in China. While the specific biological target and chemical structure have not been publicly disclosed, the drug is intended to manage conditions associated with excessive gastric acid production by leveraging the potential pharmacokinetic advantages of deuteration.